Orpathys approved in China for lung cancer
23 June 2021 07:00 BST Orpathys approved in China for patientswith lung cancer and MET gene alterations First-in-class approval in China in this setting and first regulatory approvalfor the oral, potent and highly selective MET tyrosine kinase inhibitor AstraZeneca and HUTCHMED’s Orpathys (savolitinib) has been granted conditional approval in China to treat patients with non-small cell lung cancer (NSCLC) with MET exon 14 skipping alterations who have progressed following prior systemic therapy or are unable to receive chemotherapy. This approval follows a priority review